☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - July 2015

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Adalimumab (Humira®) has been accepted for restricted use in the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. The restriction limits use individuals with severe disease as defined by a total Psoriasis Area Severity Index (PASI) score of ≥10 and a Dermatology Life Quality Index (DLQI) of >10.

Riociguat (Adempas®) has been accepted for restricted use in the treatment of pulmonary arterial hypertension (PAH) as monotherapy or in combination with endothelin receptor antagonists in adult patients with World Health Organisation Functional Class (WHO FC) II to III to improve exercise capacity. It is restricted to initiation and prescribing by specialists in the Scottish Pulmonary Vascular Unit or by similar specialists.

Rivaroxaban (Xarelto®) has been rejected for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers in combination with aspirin alone or with aspirin plus clopidogrel or ticlopidine. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - July 2015' by emailShare 'SMC Update - July 2015' on FacebookShare 'SMC Update - July 2015' on TwitterShare 'SMC Update - July 2015' on LinkedInShare 'SMC Update - July 2015' on reddit


No Comments to “SMC Update - July 2015”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.